UB513
ProductVisepegenatide Injection
IndicationsType 2 diabetes mellitus; Obesity
TherapeuticsMetabolic & Endocrinology
GMPCN - NMPA
RegistrationChina
ModalitiesPeptide
Exclusive Summary
- Global IP & Freedom to Operate: An innovative drug with global proprietary rights, allowing immediate market entry without waiting for patent expiries or risking infringement, ideal for exclusive regional distribution.
- US Clinical Validation & No Ethnic Difference: The only Chinese GLP-1 to complete Phase II trials in the US, proving no ethnic difference, which significantly lowers regulatory hurdles and facilitates bridging studies in global markets.
- Superior Compliance & Guideline Alignment: Offers a once-weekly injection advantage over daily competitors, aligning with ADA/EASD guidelines for T2DM and Obesity management, ensuring high patient adherence.
- Cost-Effectiveness & Supply Stability: Leverages Chinese manufacturing efficiency to offer a competitive price point against MNC incumbents, making premium GLP-1 therapy accessible in price-sensitive emerging markets.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →